FDA recall, , Moderate risk
Imprimis NJOF Dexamethasone Moxifloxacin and Tri-Moxi+ Intraocular Injections
Dexamethasone Moxifloxacin intraocular injections contain particulate matter - glass like particles.
Summary by Recall Canary from the FDA notice
What happened
Imprimis NJOF, LLC of Ledgewood, New Jersey, recalled Tri-Moxi+ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/0.6 mL) Single-Use Intraocular Injection, Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, and Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL Single-Use Intraocular Injection due to the presence of particulate matter - glass like particles.
The recall began on December 18, 2025, and was added to the FDA's Enforcement Report on January 2, 2026. The products were distributed nationwide in the U.S.
2 photos
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
3 products
Match the lot code and NDC listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Dexamethasone Moxifloxacin
- Strength
- 1 mg/mL
- NDC
- 71384-512-0.1
- Lot code
- 25MAY051
- 25AUG003
Tri-Moxi+¿ (Triamcinolone
- Strength
- 9 mg
- NDC
- 71384-746-06
- Lot code
- 25JAN033A
- 25JAN033B
Dexamethasone Moxifloxacin Ketorolac
- Strength
- 1 mg/mL
- NDC
- 71384-513-01
- Lot code
- 25APR001A
- 25APR001B
Recall details
- Company began the recall
- Sold in
U.S Nationwide
- Company
- Imprimis NJOF, LLCLedgewood, New Jersey
- Hazard
- Foreign object
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 98181
- Recall numbers
- D-0249-2026 to D-0251-2026
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Listed on Recall Canary
